|Bid||17.68 x 1100|
|Ask||18.70 x 1400|
|Day's Range||17.56 - 17.91|
|52 Week Range||9.80 - 31.56|
|Beta (5Y Monthly)||1.94|
|PE Ratio (TTM)||17.69|
|Earnings Date||Aug 10, 2016 - Aug 15, 2016|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Mar 12, 2020|
|1y Target Est||19.03|
(NYSE: CAE) (TSX: CAE) – CAE will release its fiscal year 2021 second quarter results on Tuesday, November 10, 2020. A conference call will be held on the same day at 1 p.m. Eastern Time (ET) to provide analysts and institutional investors with a review of CAE's performance and outlook.
TALTZ is now approved to treat patients across the axSpA spectrum, including ankylosing spondylitis and non-radiographic axSpA TORONTO, Oct. 19, 2020 /CNW/ - On October 14, 2020, Health Canada approved TALTZ® for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have responded inadequately to, or are intolerant to conventional therapy.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...